Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2)

PHASE3CompletedINTERVENTIONAL
Enrollment

670

Participants

Timeline

Start Date

December 22, 2020

Primary Completion Date

September 28, 2021

Study Completion Date

September 28, 2021

Conditions
Covid19Coronavirus
Interventions
DRUG

Fluvoxamine

Up to 200mg per day (2 capsules per day) as tolerated, for approximately 15 days

DRUG

Placebo

Will take 2 capsules per day as tolerated for approximately 15 days

Trial Locations (5)

60611

Northwestern University, Chicago

63110

Washington University School of Medicine, St Louis

84108

University of Utah, Salt Lake City

98109

Fred Hutchinson, Seattle

H4A3S9

McGill University Health Center, Montreal

All Listed Sponsors
collaborator

Covid-19 Early Treatment Fund

OTHER

collaborator

McGill University

OTHER

collaborator

Cures Within Reach

OTHER

lead

Washington University School of Medicine

OTHER

NCT04668950 - Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2) | Biotech Hunter | Biotech Hunter